Literature DB >> 27112998

Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications.

Stella T Chou1, Ross M Fasano2.   

Abstract

Red blood cell (RBC) transfusion therapy is a key component of comprehensive management of patients with sickle cell disease (SCD) and has increased over time as a means of primary and secondary stroke prevention. RBC transfusions also prove to be lifesaving for many acute sickle cell-related complications. Although episodic and chronic transfusion therapy has significantly improved the morbidity and mortality of patients with SCD, transfusions are not without adverse effects. This review addresses RBC transfusion methods, evidence-based and/or expert panel-based consensus on indications for chronic and episodic transfusion indications, and strategies to prevent and manage transfusion-related complications.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alloimmunization; Iron overload; Red blood cell transfusion; Sickle cell disease

Mesh:

Year:  2016        PMID: 27112998     DOI: 10.1016/j.hoc.2016.01.011

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  30 in total

1.  A locus on chromosome 5 shows African ancestry-limited association with alloimmunization in sickle cell disease.

Authors:  Lesedi M Williams; Zhihua Qi; Ken Batai; Stanley Hooker; Nancy J Hall; Roberto F Machado; Alice Chen; Sally Campbell-Lee; Yongtao Guan; Rick Kittles; Neil A Hanchard
Journal:  Blood Adv       Date:  2018-12-26

Review 2.  Knowledge insufficient: the management of haemoglobin SC disease.

Authors:  Lydia H Pecker; Beverly A Schaefer; Lori Luchtman-Jones
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

Review 3.  Neurological and Neurosurgical Emergencies in Patients with Hematological Disorders.

Authors:  Martha L Cruz; Shama Farooq; Fernando D Testai
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

4.  Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease.

Authors:  Raisa Balbuena-Merle; Susanna A Curtis; Lesley Devine; David R Gibb; Matthew S Karafin; Chance John Luckey; Christopher A Tormey; Alexa J Siddon; John D Roberts; Jeanne E Hendrickson
Journal:  Transfusion       Date:  2019-07-29       Impact factor: 3.157

5.  Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD.

Authors:  Yunfeng Liu; Hui Zhong; Weili Bao; Avital Mendelson; Xiuli An; Patricia Shi; Stella T Chou; Deepa Manwani; Karina Yazdanbakhsh
Journal:  Blood       Date:  2019-05-10       Impact factor: 22.113

6.  Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.

Authors:  Matthew S Karafin; Matt Westlake; Ronald G Hauser; Christopher A Tormey; Philip J Norris; Nareg H Roubinian; Yanyun Wu; Darrell J Triulzi; Steve Kleinman; Jeanne E Hendrickson
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

Review 7.  Neurologic Complications of Sickle Cell Disease.

Authors:  Shama Farooq; Fernando D Testai
Journal:  Curr Neurol Neurosci Rep       Date:  2019-02-28       Impact factor: 5.081

Review 8.  Not all red cells sickle the same: Contributions of the reticulocyte to disease pathology in sickle cell anemia.

Authors:  Marcus A Carden; Ross M Fasano; Emily Riehm Meier
Journal:  Blood Rev       Date:  2019-11-05       Impact factor: 8.250

Review 9.  Transfusion Support of Minority Patients: Extended Antigen Donor Typing and Recruitment of Minority Blood Donors.

Authors:  Jenna Khan; Meghan Delaney
Journal:  Transfus Med Hemother       Date:  2018-07-19       Impact factor: 3.747

10.  An Experimental-Computational Approach to Quantify Blood Rheology in Sickle Cell Disease.

Authors:  Marisa S Bazzi; José M Valdez; Victor H Barocas; David K Wood
Journal:  Biophys J       Date:  2020-10-20       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.